Stavrogianni Konstantina, Kitsos Dimitrios K, Giannopapas Vasileios, Smyrni Vassiliki, Chasiotis Athanasios K, Akrivaki Alexandra, Dimitriadou Evangelia-Makrina, Zompola Christina, Tzartos John S, Tsivgoulis Georgios, Giannopoulos Sotirios
Second Department of Neurology, School of Medicine, Attikon University Hospital, National and Kapodistrian University of Athens, 157 72 Athens, Greece.
Department of Physiology, Faculty of Medicine, School of Health Sciences, University of Ioannina, 451 10 Ioannina, Greece.
J Clin Med. 2025 Mar 20;14(6):2121. doi: 10.3390/jcm14062121.
Multiple Sclerosis (MS) is associated with a wide range of debilitating symptoms, and conventional therapies often fail to adequately address the disease's multifaceted challenges. Cannabidiol (CBD) 13.0% + Delta9-tetrahydrocannabinol (THC) 9.0% (CBD13/THC9), a vaporized cannabis-based medicinal product, presents a novel therapeutic option for managing MS symptoms. This single-center longitudinal study followed 69 MS patients over a six-month period. Participants were assessed at treatment initiation and at three- and six-month intervals. Key measures included muscle spasticity, urine bladder dysfunction, and the evaluation of disability progression rate. The evaluation included the Modified Ashworth Scale (MAS), the Post Void Residual (PVR) volume, and the Expanded Disability Status Scale (EDSS). Significant improvement was observed across all outcome assessments. The EDSS score was decreased over time ( = 0.009), indicating a slight reduction in disability progression rate, while MAS scores showed substantial improvement in muscle spasticity ( < 0.001). Urine bladder function improved significantly, with PVR volume showing notable improvement between baseline and the six-month assessment ( < 0.001). Correlation analyses revealed that a gradual increase in vaporized CBD13/THC9 dose was correlated with slightly lower EDSS scores, while the adverse effects were negatively associated with the frequency of cannabinoid use. Finally, patients who were smokers used CBD13/THC9 more frequently. The vaporized CBD13/THC9 formulation demonstrated notable efficacy in slightly improving disability progression rate via reduction in muscle spasticity and urine bladder dysfunction in MS patients. This highlights its addon therapeutic value during rehabilitation in MS patients with debilitating disability symptoms.
多发性硬化症（MS）与多种使人衰弱的症状相关，传统疗法往往无法充分应对该疾病多方面的挑战。大麻二酚（CBD）13.0%+Δ9-四氢大麻酚（THC）9.0%（CBD13/THC9），一种基于大麻的汽化药用产品，为管理MS症状提供了一种新的治疗选择。这项单中心纵向研究在六个月的时间里跟踪了69名MS患者。在治疗开始时以及每隔三个月和六个月对参与者进行评估。关键指标包括肌肉痉挛、膀胱功能障碍以及残疾进展率评估。评估包括改良Ashworth量表（MAS）、排尿后残余尿量（PVR）以及扩展残疾状态量表（EDSS）。在所有结果评估中均观察到显著改善。随着时间推移，EDSS评分降低（ = 0.009），表明残疾进展率略有降低，而MAS评分显示肌肉痉挛有显著改善（ < 0.001）。膀胱功能显著改善，PVR体积在基线和六个月评估之间有显著改善（ < 0.001）。相关性分析显示，汽化CBD13/THC9剂量的逐渐增加与略低的EDSS评分相关，而不良反应与大麻素使用频率呈负相关。最后，吸烟者使用CBD13/THC9更频繁。汽化CBD13/THC9制剂在通过减轻MS患者的肌肉痉挛和膀胱功能障碍来略微改善残疾进展率方面显示出显著疗效。这突出了其在患有使人衰弱的残疾症状的MS患者康复过程中的附加治疗价值。
